Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 in MSI-H advanced solid tumors
ChiCTR-OIC-17013249Phase 2Recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Nov 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in Nonhematologic neoplasms and microsatellite instability-high cancer, sponsored by Shanghai East Hospital. Primary endpoint: Objective response rate. Started Nov 2017; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
Nonhematologic neoplasmsmicrosatellite instability-high cancer
Beyond the preview
Go deeper on ChiCTR-OIC-17013249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17013249.